Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental hematology"
DOI: 10.1016/j.exphem.2021.06.004
Abstract: Targeting Januskinase (JAK) has revolutionized the treatment of myeloproliferative neoplasms. The JAK inhibitor ruxolitinib improved the outcome and quality of life of patients dramatically at the cost of increased risk of infections. As previously shown,… read more here.
Keywords: pacritinib; ruxolitinib pacritinib; jak inhibitor; dendritic cells ... See more keywords